Cassava Sciences Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while ProShares UltraPro Short QQQ ETF trades at $37.17. Which is the better fit depends on your goals.
| FLNA | SQQQ | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $92.95 |
52-Week Low | $0.87 | $36.31 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
SQQQ trades at $37.05, down 1.83% on the day, reflecting its inverse leveraged structure designed to move opposite the Nasdaq-100. The technical picture remains bearish with moving averages signaling continued downward pressure, though oversold conditions suggest potential for short-term bounces. Recent news highlights SQQQ's role as a tactical hedging tool rather than a long-term investment, with significant erosion risk due to daily reset mechanisms.
SQQQ serves as a high-risk tactical instrument for bearish Nasdaq-100 bets, with success dependent on precise market timing. The ETF faces structural decay from daily rebalancing, making it unsuitable for buy-and-hold strategies. Current market volatility and tech sector concerns create potential short-term opportunities, but long-term holders have historically suffered substantial losses.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →